Gelstat Overview
- Status
-
Public
- Employees
-
11
- Stock Symbol
-
GSAC
- Investments
-
2
Gelstat General Information
Description
GelStat Corp is a consumer healthcare company operating in the US. It is engaged in the development and marketing of over-the-counter (OTC) and other non-prescription consumer healthcare products. The company's lead product is Gelstat Migraine, which is a patented OTC homeopathic drug for use as a first-line, acute treatment for migraine and migraine-like headaches. The Gelstat Migraine is developed to provide acute relief from headache pain as well as other symptoms associated with a migraine. The other products of the company include CHEWS 2 LOSE, which is a diet aide in the form of an all-natural appetite suppressant gum; All Natural Speed which targets specific quick-fix energy user groups; and GelStat Sleep, which provides relief from sleep disorders and their associated symptoms.
Contact Information
Website
www.gelstat.com
Formerly Known As
Gelstat Corporation
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Pharmaceuticals
Stock Exchange
PINX
Primary Office
- 3557 SW Corporate Parkway
- Palm City, FL 34990
- United States
+1 (772) 000-0000
Gelstat Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| 1.57M |
Gelstat Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2008 | FY 2008 31-Dec-2008 | FY 2007 31-Dec-2007 | FY 2006 31-Dec-2006 |
|---|---|---|---|---|
| EV | 2,185 | |||
| Revenue | 23 | 23 | 18 | 234 |
| EBITDA | (417) | (417) | (1,039) | (1,761) |
| Net Income | (463) | (463) | (1,083) | (1,818) |
| Total Assets | 47 | 47 | 103 | 170 |
| Total Debt | 459 | 459 | 472 | 472 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Gelstat Patents
Gelstat Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2003284322-A1 | Dietary supplement comprising parthenolide | Abandoned | 05-Nov-2002 | 000000000 | |
| EP-1558270-A1 | Dietary supplement comprising parthenolide | Withdrawn | 05-Nov-2002 | 000000000 | |
| US-20040086579-A1 | Orally administering the oral dosage comprising parthenolide; retaining at least a portion of the administered oral dosage in the oral cavity for a time sufficient to allow absorption of parthenolide by oral mucosal tissues | Abandoned | 05-Nov-2002 | 000000000 | |
| CA-2503644-A1 | Dietary supplement comprising parthenolide | Abandoned | 05-Nov-2002 | 000000000 | |
| US-20060013904-A1 | Treatment method comprising administering feverfew to oral mucosal tissues in solid or semi-solid form | Abandoned | 05-Nov-2002 | A61K36/82 |
Gelstat Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Laurence Gershman | Chief Executive Officer & Chairman | ||
| Gerald Kieft | Chief Financial Officer & Board Member |
Gelstat Board Members (2)
| Name | Representing | Role | Since |
|---|---|---|---|
| 000000 00000 | Self | Chief Financial Officer & Board Member | 000 0000 |
| 00000000 00000000 | Gelstat | Chief Executive Officer & Chairman | 000 0000 |
Gelstat Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Gelstat Acquisitions (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000 000000 | 08-Jul-2014 | 0000000000 | 00.00 | Drug Discovery | 00000000 |
| CBD Life Sciences | 23-Oct-2013 | Merger/Acquisition | Food Products | 000000 00 |